News Headlines Article

Maker of addictive fentanyl spray agrees to pay $225 million for prescriptions-for-cash scheme
The Washington Post

The opioid manufacturer Insys Therapeutics has agreed to pay some $225 million to end criminal and civil investigations into allegations that it used a system of bribes to get doctors to illegally prescribe its highly addictive product, federal officials announced Wednesday.

As part of the resolution, the company will plead guilty to five counts of mail fraud, admitting that a speaker program it used to increase its brand awareness was actually a “vehicle to pay bribes and kickbacks to targeted practitioners,” who were willing to increase prescriptions for Subsys, the company’s powerful fentanyl spray, according to a news release from the Justice Department.

The spray had been approved by the Food and Drug Administration for treating the severe pain of terminal cancer patients. But the company came up with ways to get doctors to write prescriptions for patients who didn’t need the drug, prosecutors have charged.